Clinical and Microbiological End Points in the Treatment of Pneumonia
Open Access
- 1 December 2008
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 47 (S3), S207-S209
- https://doi.org/10.1086/591406
Abstract
The US Food and Drug Administration is reviewing its criteria for evaluating new antibiotics for the treatment of bacterial pneumonia. Although there are descriptions of hundreds of comparative studies of various antimicrobials, there is surprisingly little scientific literature on how the evaluations should be done. This brief contribution outlines areas for further consideration as new drugs are evaluated.Keywords
This publication has 12 references indexed in Scilit:
- Diagnostic Value of Microscopic Examination of Gram-Stained Sputum and Sputum Cultures in Patients with Bacteremic Pneumococcal PneumoniaClinical Infectious Diseases, 2004
- The Community-Acquired Pneumonia Symptom QuestionnaireChest, 2002
- Time to Clinical Stability in Patients Hospitalized With Community-Acquired PneumoniaJAMA, 1998
- Pneumonia and Acute Febrile Tracheobronchitis Due to Haemophilus influenzaeAnnals of Internal Medicine, 1983
- PNEUMOCOCCAL TYPING AND THE PROBLEM OF ENDOGENOUS OR EXOGENOUS REINFECTION IN CHRONIC BRONCHITISThe Lancet, 1971
- Recurrent PneumoniaAnnals of Internal Medicine, 1969
- Pneumococcal Bacteremia with Especial Reference to Bacteremic Pneumococcal PneumoniaAnnals of Internal Medicine, 1964
- Moderate and Severe Pneumococcal PneumoniaArchives of Internal Medicine, 1961
- Pneumococcal Pneumonia Treated with AntibioticsNew England Journal of Medicine, 1954
- THE RELATIVE EFFICACY OF ERYTHROMYCIN (ILOTYCIN) AND OF PENICILLIN IN THE TREATMENT OF PNEUMOCOCCAL LOBAR PNEUMONIAThe American Journal of the Medical Sciences, 1953